{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:40:31Z","timestamp":1788306031492,"version":"build-2803163510"},"reference-count":18,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Multisystem inflammatory syndrome (MIS) is a new systemic inflammatory acute onset disease that mainly affects children (MIS-C) and, at a lesser frequency, adults (MIS-A); it typically occurs 3\u20136 weeks after acute SARS-CoV infection. It has been postulated and shown in adults that MIS may occur after SARS-CoV-2 vaccination (MIS-V). Our current case is one of the first published cases with a multisystem inflammatory syndrome in an 18-year-old adolescent after the SARS-CoV-2 vaccine from Pfizer\/BionTech (BNT162b2), who fulfills the published level 1 criteria for a definitive disease: age &lt; 21 years, fever &gt; 3 consecutive days, pericardial effusion, elevated CRP\/NT-BNP\/Troponin T\/D-dimeres, cardiac involvement, and positive SARS-CoV-2 antibodies. The disease starts 10 weeks after the second vaccination, with a fever (up to 40 \u00b0C) and was treated with amoxicillin for suspected pneumonia. The SARS CoV-2-PCR and several antigen tests were negative. With an ongoing fever, he was hospitalized 14 days later. A pericardial effusion (10 mm) was diagnosed by echocardiography. The C-reactive protein (174 mg\/L), NT-BNP (280 pg\/mL), and Troponin T (28 pg\/mL) values were elevated. Due to highly elevated D-dimeres (&gt;35,000 \u03bcg\/L), a pulmonary embolism was excluded by thoracal computer tomography. If the boy did not improve with intravenous antibiotics, he was treated with intravenous immunoglobulins; however, the therapy was discontinued after 230 mg\/kg if he developed high fever and hypotension. A further specialized clinic treated him with colchicine and ibuprofen. The MIS-V was discovered late, 4 months after the onset of the disease. As recently shown in four children with MIS-C after SARS-CoV-2 infection and a girl with Hashimoto thyroiditis after BNT162b2 vaccination, we found elevated functional autoantibodies against G-protein-coupled receptors that may be important for pathophysiology but are not conclusive for the diagnosis of MIS-C. Conclusion: We are aware that a misattribution of MIS-V as a severe complication of coronavirus vaccination can lead to increased vaccine hesitancy and blunt the global COVID-19 vaccination drive. However, the pediatric population is at a higher risk for MIS-C and a very low risk for COVID-19 mortality. The publication of such cases is very important to make doctors aware of this complication of the vaccination, so that therapy with intravenous immunoglobulins can be initiated at an early stage.<\/jats:p>","DOI":"10.3390\/vaccines9111353","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T02:43:31Z","timestamp":1637289811000},"page":"1353","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Autoantibody Release in Children after Corona Virus mRNA Vaccination: A Risk Factor of Multisystem Inflammatory Syndrome?"],"prefix":"10.3390","volume":"9","author":[{"given":"Reiner","family":"Buchhorn","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Caritas-Krankenhaus Bad Mergentheim, Uhlandstra\u00dfe 7, 97980 Bad Mergentheim, Germany"},{"name":"Praxis f\u00fcr Kinder- und Jugendmedizin, Kinderkardiologie und Erwachsene Mit Angeborenen Herzfehlern, Am Bahnhof 1, 74670 Forchtenberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Meyer","sequence":"additional","affiliation":[{"name":"CellTrend GmbH, 14943 Luckenwalde, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Schulze-Forster","sequence":"additional","affiliation":[{"name":"CellTrend GmbH, 14943 Luckenwalde, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Junker","sequence":"additional","affiliation":[{"name":"CellTrend GmbH, 14943 Luckenwalde, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Heidecke","sequence":"additional","affiliation":[{"name":"CellTrend GmbH, 14943 Luckenwalde, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1016\/j.vaccine.2021.01.054","article-title":"Multisystem inflammatory syndrome in children and adults (MIS-C\/A): Case definition & guidelines for data collection, analysis, and presentation of immunization safety data","volume":"39","author":"Vogel","year":"2021","journal-title":"Vaccine"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.3201\/eid2707.210594","article-title":"Multisystem Inflammatory Syndrome after SARS-CoV-2 Infection and COVID-19 Vaccination","volume":"27","author":"Salzman","year":"2021","journal-title":"Emerg. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., Hern\u00e1n, M.A., Lipsitch, M., Kohane, I., and Netzer, D. (2021). Safety of the BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Setting. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2110475"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41569-020-00435-x","article-title":"Myocarditis and inflammatory cardiomyopathy: Current evidence and future directions","volume":"18","author":"Ammirati","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e006155","DOI":"10.1161\/CIRCHEARTFAILURE.119.006155","article-title":"\u03b2(1)-Adrenoreceptor Autoantibodies in Heart Failure: Physiology and Therapeutic Implications","volume":"13","author":"Dordevic","year":"2020","journal-title":"Circ. Heart Fail."},{"key":"ref_6","unstructured":"Buchhorn, R., Meyer, C., Heidecke, H., and Willaschek, C. (2021). Functional autoantibodies against G-protein coupled receptors in children with complications after SARS-CoV-2 infections. Isr. Med. Assoc. J., in press."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Dotan, A., Muller, S., Kanduc, D., David, P., Halpert, G., and Shoenfeld, Y. (2021). The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun. Rev.","DOI":"10.1016\/j.autrev.2021.102792"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100100","DOI":"10.1016\/j.jtauto.2021.100100","article-title":"Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms","volume":"4","author":"Wallukat","year":"2021","journal-title":"J. Transl. Autoimmun."},{"key":"ref_9","first-page":"1345","article-title":"Anti-\u03b2-adrenoceptors autoimmunity causing \u2018idiopathic\u2019 arrhythmias and cardiomyopathy","volume":"76","author":"Brisinda","year":"2012","journal-title":"Circ. J. Off. J. Jpn. Circ. Soc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2741\/e849","article-title":"Beta(1)-adrenergic receptor antibodies in children with dilated cardiomyopathy","volume":"11","author":"Camino","year":"2019","journal-title":"Front. Biosci."},{"key":"ref_11","first-page":"100094","article-title":"Manifestations of thyroid disease post COVID-19 illness: Report of Hashimoto thyroiditis, Graves\u2019 disease, and subacute thyroiditis","volume":"22","author":"Feghali","year":"2021","journal-title":"J. Clin. Transl. Endocrinol. Case Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2796.2010.02321.x","article-title":"The pulse of inflammation: Heart rate variability, the cholinergic anti-inflammatory pathway and implications for therapy","volume":"269","author":"Huston","year":"2011","journal-title":"J. Intern. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.hjc.2020.12.004","article-title":"COVID-19-related myocarditis and cholinergic anti-inflammatory pathways","volume":"62","author":"Liu","year":"2021","journal-title":"Hell. J. Cardiol. HJC = Hell. Kardiol. Ep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s10753-020-01396-6","article-title":"The Role of \u03b17nAChR-Mediated Cholinergic Anti-inflammatory Pathway in Immune Cells","volume":"44","author":"Wu","year":"2021","journal-title":"Inflammation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"112009","DOI":"10.1016\/j.fct.2021.112009","article-title":"Nicotinic cholinergic system and COVID-19: In silico identification of interactions between \u03b17 nicotinic acetylcholine receptor and the cryptic epitopes of SARS-Co-V and SARS-CoV-2 Spike glycoproteins","volume":"149","author":"Lagoumintzis","year":"2021","journal-title":"Food Chem. Toxicol. Int. J. Publ. Br. Ind. Biol. Res. Assoc."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Buchhorn, R., Willaschek, C., and Baumann, C. (2021). SARS-CoV-2 infections and the autonomic nervous system. Mon. Kinderheilkd, 1\u20134.","DOI":"10.1007\/s00112-021-01197-7"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Buchhorn, R., Baumann, C., and Willaschek, C. (2020). Heart Rate Variability in a Patient with Coronvirus Disease 2019. Int. Cardiovasc. Forum J., 20.","DOI":"10.17987\/icfj.v20i0.685"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14738\/jbemi.74.8589","article-title":"An Algorithm to Predict Life-Threatening Complications using Heart Rate Variability and the Circadian Heart Rate Difference with a Special Interest on COVID-19, SUDEP, Children with Congenital Heart Disease and Obesity","volume":"7","author":"Buchhorn","year":"2020","journal-title":"J. Biomed. Eng. Med. Imaging"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/11\/1353\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:32:21Z","timestamp":1760167941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/11\/1353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":18,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["vaccines9111353"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9111353","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,18]]}}}